抗CD20モノクローナル抗体（mAB）の世界市場 2024-2028

概要

抗CD20モノクローナル抗体（mAB）市場は、2023年から2028年にかけて114億2,515万米ドル、予測期間中のCAGRは10.31%で成長すると予測されています。

当レポートでは、抗CD20モノクローナル抗体（mAB）市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、併用療法の増加、抗CD20mABの標的親和性・特異性の高さ、強力なパイプラインと最近の承認によって牽引されています。

当レポートでは、今後数年間の抗CD20モノクローナル抗体（mAB）市場成長を牽引する主な要因として、治療領域に対する意識の高まりを挙げています。また、償還制度や患者支援制度の存在、CD20二重特異性抗体市場の発展は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 抗CD20モノクローナル抗体（mAB）の世界市場 2018-2022
• 製品別セグメント分析 2018-2022
• タイプ別セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：製品別

• 市場セグメント
• 比較：製品別
• 腫瘍学：市場規模と予測 2023-2028
• 神経内科：市場規模と予測 2023-2028
• 免疫学：市場規模と予測 2023-2028
• 市場機会：製品別

第7章 市場セグメンテーション：タイプ別

• 市場セグメント
• 比較：タイプ別
• 第一世代抗CD20モノクローナル抗体：市場規模と予測 2023-2028
• 第二世代抗CD20モノクローナル抗体：市場規模と予測 2023-2028
• 第三世代抗CD20モノクローナル抗体：市場規模と予測 2023-2028
• 市場機会：タイプ別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• カナダ：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• 市場機会：地域別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Acrotech Biopharma Inc.
• Amgen Inc.
• AstraZeneca Plc
• Celltrion Healthcare Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Fosun International Ltd.
• Genmab AS
• IGM Biosciences Inc.
• JSC BIOCAD
• LFB SA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Spectrum Pharmaceuticals Inc.
• TG Therapeutics Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market by Geography
• Exhibits5: Executive Summary - Chart on Market Segmentation by Product
• Exhibits6: Executive Summary - Chart on Market Segmentation by Type
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Product - Market share 2023-2028 (%)
• Exhibits31: Data Table on Product - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Product
• Exhibits33: Data Table on Comparison by Product
• Exhibits34: Chart on Oncology - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Oncology - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Neurology - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on Neurology - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on Neurology - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Neurology - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Immunology - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Immunology - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Immunology - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Immunology - Year-over-year growth 2023-2028 (%)
• Exhibits46: Market opportunity by Product ($ million)
• Exhibits47: Data Table on Market opportunity by Product ($ million)
• Exhibits48: Chart on Type - Market share 2023-2028 (%)
• Exhibits49: Data Table on Type - Market share 2023-2028 (%)
• Exhibits50: Chart on Comparison by Type
• Exhibits51: Data Table on Comparison by Type
• Exhibits52: Chart on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits60: Chart on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits61: Data Table on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibits62: Chart on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits63: Data Table on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibits64: Market opportunity by Type ($ million)
• Exhibits65: Data Table on Market opportunity by Type ($ million)
• Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits67: Chart on Market share by geography 2023-2028 (%)
• Exhibits68: Data Table on Market share by geography 2023-2028 (%)
• Exhibits69: Chart on Geographic comparison
• Exhibits70: Data Table on Geographic comparison
• Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits103: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibits104: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibits105: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits106: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits107: Market opportunity by geography ($ million)
• Exhibits108: Data Tables on Market opportunity by geography ($ million)
• Exhibits109: Impact of drivers and challenges in 2023 and 2028
• Exhibits110: Overview on Criticality of inputs and Factors of differentiation
• Exhibits111: Overview on factors of disruption
• Exhibits112: Impact of key risks on business
• Exhibits113: Vendors covered
• Exhibits114: Matrix on vendor position and classification
• Exhibits115: Acrotech Biopharma Inc. - Overview
• Exhibits116: Acrotech Biopharma Inc. - Product / Service
• Exhibits117: Acrotech Biopharma Inc. - Key offerings
• Exhibits118: Amgen Inc. - Overview
• Exhibits119: Amgen Inc. - Product / Service
• Exhibits120: Amgen Inc. - Key offerings
• Exhibits121: AstraZeneca Plc - Overview
• Exhibits122: AstraZeneca Plc - Product / Service
• Exhibits123: AstraZeneca Plc - Key news
• Exhibits124: AstraZeneca Plc - Key offerings
• Exhibits125: Celltrion Healthcare Co. Ltd. - Overview
• Exhibits126: Celltrion Healthcare Co. Ltd. - Product / Service
• Exhibits127: Celltrion Healthcare Co. Ltd. - Key offerings
• Exhibits128: F. Hoffmann La Roche Ltd. - Overview
• Exhibits129: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits130: F. Hoffmann La Roche Ltd. - Key news
• Exhibits131: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits132: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits133: Fosun International Ltd. - Overview
• Exhibits134: Fosun International Ltd. - Product / Service
• Exhibits135: Fosun International Ltd. - Key offerings
• Exhibits136: Genmab AS - Overview
• Exhibits137: Genmab AS - Key offerings
• Exhibits138: IGM Biosciences Inc. - Overview
• Exhibits139: IGM Biosciences Inc. - Product / Service
• Exhibits140: IGM Biosciences Inc. - Key offerings
• Exhibits141: JSC BIOCAD - Overview
• Exhibits142: JSC BIOCAD - Product / Service
• Exhibits143: JSC BIOCAD - Key offerings
• Exhibits144: LFB SA - Overview
• Exhibits145: LFB SA - Product / Service
• Exhibits146: LFB SA - Key offerings
• Exhibits147: Novartis AG - Overview
• Exhibits148: Novartis AG - Business segments
• Exhibits149: Novartis AG - Key offerings
• Exhibits150: Novartis AG - Segment focus
• Exhibits151: Pfizer Inc. - Overview
• Exhibits152: Pfizer Inc. - Product / Service
• Exhibits153: Pfizer Inc. - Key news
• Exhibits154: Pfizer Inc. - Key offerings
• Exhibits155: Regeneron Pharmaceuticals Inc. - Overview
• Exhibits156: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibits157: Regeneron Pharmaceuticals Inc. - Key offerings
• Exhibits158: Spectrum Pharmaceuticals Inc. - Overview
• Exhibits159: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibits160: Spectrum Pharmaceuticals Inc. - Key offerings
• Exhibits161: TG Therapeutics Inc. - Overview
• Exhibits162: TG Therapeutics Inc. - Product / Service
• Exhibits163: TG Therapeutics Inc. - Key offerings
• Exhibits164: Inclusions checklist
• Exhibits165: Exclusions checklist
• Exhibits166: Currency conversion rates for US$
• Exhibits167: Research methodology
• Exhibits168: Validation techniques employed for market sizing
• Exhibits169: Information sources
• Exhibits170: List of abbreviations

Abstract

The Anti-CD20 monoclonal antibodies (mABs) market is forecasted to grow by USD 11425.15 mn during 2023-2028, accelerating at a CAGR of 10.31% during the forecast period. The report on the Anti-CD20 monoclonal antibodies (mABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of Anti-CD20 mABs, and strong pipeline and recent approvals.

Technavio's Anti-CD20 monoclonal antibodies (mABs) market is segmented as below:

By Product

• Oncology
• Neurology
• Immunology

By Type

• First generation Anti-CD20 monoclonal antibody
• Second generation Anti-CD20 monoclonal antibody
• Third generation Anti-CD20 monoclonal antibody

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing awareness about therapeutic areas as one of the prime reasons driving the Anti-CD20 monoclonal antibodies (mABs) market growth during the next few years. Also, the presence of reimbursement and patient assistance programs and the development of cd20 bispecific antibodies will lead to sizable demand in the market.

The report on the Anti-CD20 monoclonal antibodies (mABs) market covers the following areas:

• Anti-CD20 monoclonal antibodies (mABs) market sizing
• Anti-CD20 monoclonal antibodies (mABs) market forecast
• Anti-CD20 monoclonal antibodies (mABs) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Anti-CD20 monoclonal antibodies (mABs) market vendors that include Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.. Also, the Anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market by Geography
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global anti-CD20 monoclonal antibodies (mABs) market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 - 2022 ($ million)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Oncology - Market size and forecast 2023-2028
• Exhibit 34: Chart on Oncology - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
• 6.4 Neurology - Market size and forecast 2023-2028
• Exhibit 38: Chart on Neurology - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Neurology - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Neurology - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Neurology - Year-over-year growth 2023-2028 (%)
• 6.5 Immunology - Market size and forecast 2023-2028
• Exhibit 42: Chart on Immunology - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Immunology - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Immunology - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Immunology - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Product
• Exhibit 46: Market opportunity by Product ($ million)
• Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 48: Chart on Type - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
• 7.2 Comparison by Type
• Exhibit 50: Chart on Comparison by Type
• Exhibit 51: Data Table on Comparison by Type
• 7.3 First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
• Exhibit 52: Chart on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on First generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on First generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• 7.4 Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
• Exhibit 56: Chart on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Second generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Second generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• 7.5 Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028
• Exhibit 60: Chart on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 61: Data Table on Third generation anti-CD20 monoclonal antibody - Market size and forecast 2023-2028 ($ million)
• Exhibit 62: Chart on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Third generation anti-CD20 monoclonal antibody - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Type
• Exhibit 64: Market opportunity by Type ($ million)
• Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 67: Chart on Market share by geography 2023-2028 (%)
• Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Canada - Market size and forecast 2023-2028
• Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.11 China - Market size and forecast 2023-2028
• Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity by geography
• Exhibit 107: Market opportunity by geography ($ million)
• Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 109: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 114: Matrix on vendor position and classification
• 12.3 Acrotech Biopharma Inc.
• Exhibit 115: Acrotech Biopharma Inc. - Overview
• Exhibit 116: Acrotech Biopharma Inc. - Product / Service
• Exhibit 117: Acrotech Biopharma Inc. - Key offerings
• 12.4 Amgen Inc.
• Exhibit 118: Amgen Inc. - Overview
• Exhibit 119: Amgen Inc. - Product / Service
• Exhibit 120: Amgen Inc. - Key offerings
• 12.5 AstraZeneca Plc
• Exhibit 121: AstraZeneca Plc - Overview
• Exhibit 122: AstraZeneca Plc - Product / Service
• Exhibit 123: AstraZeneca Plc - Key news
• Exhibit 124: AstraZeneca Plc - Key offerings
• 12.6 Celltrion Healthcare Co. Ltd.
• Exhibit 125: Celltrion Healthcare Co. Ltd. - Overview
• Exhibit 126: Celltrion Healthcare Co. Ltd. - Product / Service
• Exhibit 127: Celltrion Healthcare Co. Ltd. - Key offerings
• 12.7 F. Hoffmann La Roche Ltd.
• Exhibit 128: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 129: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 130: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 131: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 132: F. Hoffmann La Roche Ltd. - Segment focus
• 12.8 Fosun International Ltd.
• Exhibit 133: Fosun International Ltd. - Overview
• Exhibit 134: Fosun International Ltd. - Product / Service
• Exhibit 135: Fosun International Ltd. - Key offerings
• 12.9 Genmab AS
• Exhibit 136: Genmab AS - Overview
• Exhibit 137: Genmab AS - Key offerings
• 12.10 IGM Biosciences Inc.
• Exhibit 138: IGM Biosciences Inc. - Overview
• Exhibit 139: IGM Biosciences Inc. - Product / Service
• Exhibit 140: IGM Biosciences Inc. - Key offerings
• 12.11 JSC BIOCAD
• Exhibit 141: JSC BIOCAD - Overview
• Exhibit 142: JSC BIOCAD - Product / Service
• Exhibit 143: JSC BIOCAD - Key offerings
• 12.12 LFB SA
• Exhibit 144: LFB SA - Overview
• Exhibit 145: LFB SA - Product / Service
• Exhibit 146: LFB SA - Key offerings
• 12.13 Novartis AG
• Exhibit 147: Novartis AG - Overview
• Exhibit 148: Novartis AG - Business segments
• Exhibit 149: Novartis AG - Key offerings
• Exhibit 150: Novartis AG - Segment focus
• 12.14 Pfizer Inc.
• Exhibit 151: Pfizer Inc. - Overview
• Exhibit 152: Pfizer Inc. - Product / Service
• Exhibit 153: Pfizer Inc. - Key news
• Exhibit 154: Pfizer Inc. - Key offerings
• 12.15 Regeneron Pharmaceuticals Inc.
• Exhibit 155: Regeneron Pharmaceuticals Inc. - Overview
• Exhibit 156: Regeneron Pharmaceuticals Inc. - Product / Service
• Exhibit 157: Regeneron Pharmaceuticals Inc. - Key offerings
• 12.16 Spectrum Pharmaceuticals Inc.
• Exhibit 158: Spectrum Pharmaceuticals Inc. - Overview
• Exhibit 159: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibit 160: Spectrum Pharmaceuticals Inc. - Key offerings
• 12.17 TG Therapeutics Inc.
• Exhibit 161: TG Therapeutics Inc. - Overview
• Exhibit 162: TG Therapeutics Inc. - Product / Service
• Exhibit 163: TG Therapeutics Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 164: Inclusions checklist
• Exhibit 165: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 166: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 167: Research methodology
• Exhibit 168: Validation techniques employed for market sizing
• Exhibit 169: Information sources
• 13.5 List of abbreviations
• Exhibit 170: List of abbreviations